CV THERAPEUTICS GETS RIGHTS FOR RANOLAZINE IN ASIA

A A

CV Therapeutics, Inc. has acquired rights to ranolazine in Asia following an amendment to its existing licensing agreement with Roche Palo Alto LLC adding rights to Japan, China, Korea and other Asian markets. Based on this amendment, CV Therapeutics now holds exclusive worldwide commercial rights to ranolazine.

Trading Markets (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/287192/)